Implementing pharmacist-prescriber collaboration to improve evidence-based anticoagulant use: a randomized trial.
Journal
Implementation science : IS
ISSN: 1748-5908
Titre abrégé: Implement Sci
Pays: England
ID NLM: 101258411
Informations de publication
Date de publication:
15 05 2023
15 05 2023
Historique:
received:
13
03
2023
accepted:
21
04
2023
medline:
17
5
2023
pubmed:
16
5
2023
entrez:
15
5
2023
Statut:
epublish
Résumé
Direct oral anticoagulant medications are commonly used to treat or prevent thrombotic conditions, such as pulmonary embolism, deep vein thrombosis, and atrial fibrillation. However, up to 10-15% of patients receiving these medications get unsafe doses based on a patient's kidney or liver function, potential interactions with other medications, and indication for taking the medication. Alert systems may be beneficial for improving evidence-based prescribing, but can be burdensome and are not currently able to provide monitoring after the initial prescription is written. This study will improve upon existing alert systems by testing novel medication alerts that encourage collaboration between prescribers (e.g., physicians, nurse practitioners, physician assistants) and expert pharmacists working in anticoagulation clinics. The study will also improve upon the existing alert system by incorporating dynamic long-term monitoring of patient needs and encouraging collaboration between prescribers and expert pharmacists working in anticoagulation clinics. Incorporating state-of-the-art user-centered design principles, prescribing healthcare providers will be randomized to different types of electronic health record medication alerts when a patient has an unsafe anticoagulant prescription. We will identify which alerts are most effective at encouraging evidence-based prescribing and will test moderators to tailor alert delivery to when it is most beneficial. The aims of the project are to (1) determine the effect of notifications targeting existing inappropriate DOAC prescriptions; (2) examine the effect of alerts on newly prescribed inappropriate DOACs; and (3) examine changes in the magnitude of effects over time for both the new prescription alerts and existing prescription notifications for inappropriate DOACs over the 18-month study period. Findings from this project will establish a framework for implementing prescriber-pharmacist collaboration for high-risk medications, including anticoagulants. If effectively implemented at the more than 3000 anticoagulation clinics that exist nationally, hundreds of thousands of patients taking direct oral anticoagulants stand to benefit from safer, evidence-based healthcare. NCT05351749.
Sections du résumé
BACKGROUND
Direct oral anticoagulant medications are commonly used to treat or prevent thrombotic conditions, such as pulmonary embolism, deep vein thrombosis, and atrial fibrillation. However, up to 10-15% of patients receiving these medications get unsafe doses based on a patient's kidney or liver function, potential interactions with other medications, and indication for taking the medication. Alert systems may be beneficial for improving evidence-based prescribing, but can be burdensome and are not currently able to provide monitoring after the initial prescription is written.
METHODS/DESIGN
This study will improve upon existing alert systems by testing novel medication alerts that encourage collaboration between prescribers (e.g., physicians, nurse practitioners, physician assistants) and expert pharmacists working in anticoagulation clinics. The study will also improve upon the existing alert system by incorporating dynamic long-term monitoring of patient needs and encouraging collaboration between prescribers and expert pharmacists working in anticoagulation clinics. Incorporating state-of-the-art user-centered design principles, prescribing healthcare providers will be randomized to different types of electronic health record medication alerts when a patient has an unsafe anticoagulant prescription. We will identify which alerts are most effective at encouraging evidence-based prescribing and will test moderators to tailor alert delivery to when it is most beneficial. The aims of the project are to (1) determine the effect of notifications targeting existing inappropriate DOAC prescriptions; (2) examine the effect of alerts on newly prescribed inappropriate DOACs; and (3) examine changes in the magnitude of effects over time for both the new prescription alerts and existing prescription notifications for inappropriate DOACs over the 18-month study period.
DISCUSSION
Findings from this project will establish a framework for implementing prescriber-pharmacist collaboration for high-risk medications, including anticoagulants. If effectively implemented at the more than 3000 anticoagulation clinics that exist nationally, hundreds of thousands of patients taking direct oral anticoagulants stand to benefit from safer, evidence-based healthcare.
TRIALS REGISTRATION
NCT05351749.
Identifiants
pubmed: 37189171
doi: 10.1186/s13012-023-01273-4
pii: 10.1186/s13012-023-01273-4
pmc: PMC10184412
doi:
Substances chimiques
Anticoagulants
0
Banques de données
ClinicalTrials.gov
['NCT05351749']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
16Subventions
Organisme : AHRQ HHS
ID : R18 HS028562
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
BMC Res Notes. 2018 Jul 16;11(1):478
pubmed: 30012204
Am J Health Syst Pharm. 2018 Feb 15;75(4):239-246
pubmed: 29436470
JAMA Health Forum. 2022 Jun 5;3(6):e221852
pubmed: 35977248
J Thromb Thrombolysis. 2019 Nov;48(4):629-637
pubmed: 31512200
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
BMC Med Inform Decis Mak. 2018 Jul 24;18(1):69
pubmed: 30041647
J Fam Pract. 2017 Dec;66(12):E1-E8
pubmed: 29202145
Implement Sci. 2015 Feb 12;10:21
pubmed: 25889199
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
Chest. 2016 Feb;149(2):315-352
pubmed: 26867832
J Am Heart Assoc. 2020 Mar 17;9(6):e014108
pubmed: 32146898
J Thromb Thrombolysis. 2020 May;49(4):636-643
pubmed: 31925665
Diagnosis (Berl). 2019 Aug 27;6(3):241-248
pubmed: 30485175
J Pharm Pract. 2020 Oct;33(5):647-653
pubmed: 30791808
Implement Sci. 2013 Dec 01;8:139
pubmed: 24289295
J Am Med Inform Assoc. 2019 Oct 1;26(10):1141-1149
pubmed: 31206159
J Am Med Inform Assoc. 2016 May;23(3):609-16
pubmed: 26615182
Res Pract Thromb Haemost. 2022 Sep 11;6(6):e12803
pubmed: 36110900
Implement Sci. 2018 Jan 10;13(1):7
pubmed: 29321043
Am J Med. 2019 Jul;132(7):847-855.e3
pubmed: 30776320
J Thromb Thrombolysis. 2018 Jul;46(1):7-11
pubmed: 29605836
Am J Med. 2015 Dec;128(12):1300-5.e2
pubmed: 26144101
Am J Public Health. 1999 Sep;89(9):1322-7
pubmed: 10474547
J Am Coll Cardiol. 2016 Dec 20;68(24):2597-2604
pubmed: 27978942
J Am Med Inform Assoc. 2012 Jul-Aug;19(4):635-43
pubmed: 22246963
J R Soc Med. 2018 Apr;111(4):120-124
pubmed: 29480743
J Thromb Haemost. 2015 Nov;13(11):2119-26
pubmed: 26764429
Circulation. 2019 Jul 9;140(2):e125-e151
pubmed: 30686041
J Biomed Inform. 2015 Jun;55:290-300
pubmed: 25979153